Clinical Trial Detail

NCT ID NCT02784483
Title Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Yale University
Indications

multiple myeloma

Therapies

Atezolizumab

Age Groups: adult

No variant requirements are available.